125
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      The European Repurposing Pilot Project

      Published
      conference-abstract
      1 , 1 , 2
      REPO4EU
      RExPO23
      25-26 October 2023
      Off-patent authorised medicines, off-label medicines, new treatment options to patients, Scientific Advice, Simultaneous National Scientific Advice
      Bookmark

            Abstract

            The Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA) repurposing pilot project started from discussions on a proposal for a medicines repurposing framework within the European Commission (European Commission’s Expert Group on Safe and Timely Access to Medicines for Patients, STAMP). Under the umbrella of the Pharmaceutical Committee and as a result of the discussions at the STAMP a multistakeholder Repurposing Observatory Group (RepOG) was created to oversee the implementation of the pilot project. The RepOG is composed of representatives of regulatory authorities, the European Commission, champion interest groups, industry and HTA bodies. The RepOG is led by the Spanish Agency of Medicines and Medical Devices (AEMPS) together with the EMA. In addition, there is a regulators subgroup involving representatives of EMA and the NCAs to facilitate and monitor the pilot progress.

            The overall aim of the repurposing pilot project is to support not-for-profit organisations and academia to gather or generate enough evidence to support repurposing of an already authorised medicine for a new indication. The indication should contribute to important public health needs.

            The project was opened to champions (generally seen as not-for-profit organisations). A champion can be, for example, an entity or a person from an academic unit/charity or patient organisations/learned society/research funder or payer.

            The pilot was launched in October 2021, and further to the call for candidate project submission, the eligible projects are currently under the Scientific Advice phase. A report on the advances/results on the pilot will be elaborated in due time.

            Content

            Author and article information

            Conference
            REPO4EU
            14 September 2023
            Affiliations
            [1 ] Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid (Spain) ( https://ror.org/043fs9135)
            [2 ] European Medicines Agency (EMA), Amsterdam (Netherlands) ( https://ror.org/01z0wsw92)
            Article
            10.58647/REXPO.23009
            cf3e686e-cd78-4868-89bb-5f9df54673e6
            Authors

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO23
            2
            Stockholm, Sweden
            25-26 October 2023
            History
            Product

            REPO4EU

            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pharmacology & Pharmaceutical medicine
            Off-patent authorised medicines,off-label medicines,new treatment options to patients,Scientific Advice,Simultaneous National Scientific Advice

            Comments

            Comment on this article